Privia Health Group, Inc. (PRVA) Income Statement

The sequential acceleration from 17.4% to 21.4% YoY indicates that the company's land-and-expand strategy is gaining traction, likely driven by new physician groups joining the platform. The consistent double-digit growth across the past four quarters, despite a dip to 4.6% in 2024Q4, suggests a durable growth trajectory. However, investors should monitor whether this growth is sustainable as the base of implemented providers expands, given the potential for market saturation in core geographies.

The dramatic drop in gross margin from 9.4% to 1.9% in 2026Q2 is a red flag, as it suggests a significant increase in medical costs or a shift in payer mix. While the company's model is inherently low-margin due to pass-through costs, the magnitude of the decline warrants investigation. If this trend persists, it could limit the operating leverage implied by the raised guidance. The historical average gross margin of around 10% appears more normal, but the recent quarter's deviation suggests potential timing issues in shared savings recognition.

Despite revenue growth of over 20%, operating income has not grown proportionally, with operating margins hovering around 1-2%. The increase in SG&A from $35.7M in 2025Q4 to $47.7M in 2026Q2 indicates that the company is investing heavily in its provider network and corporate infrastructure. This may be necessary to support future growth, but it also means that profitability will remain subdued until the company achieves greater scale. Investors should monitor whether SG&A growth decelerates as revenue scales, which would signal improving operating leverage.

The cost structure is heavily weighted towards COGS, which includes pass-through costs to providers and medical expenses. The spike in COGS in 2026Q2 suggests either higher medical utilization or a change in contract mix. SG&A, while smaller, has been growing, from $35.7M in 2025Q4 to $47.7M in 2026Q2, reflecting investments in sales and corporate functions. Management's expense discipline will be critical to achieving margin expansion, but the recent trend suggests costs are rising faster than revenue in some quarters.

The sharp acceleration in revenue growth from 2024Q4 to 2025Q3 indicates a strategic inflection point, likely driven by new partnerships and increased attributed lives. This period also saw operating margin peak at 2.5%, suggesting that the company was able to leverage its fixed costs during this growth spurt. However, the subsequent quarters have shown margin compression, indicating that the benefits of this inflection may be fading. Investors should assess whether the company can replicate this growth without sacrificing profitability.